BUZZ-肺癌药物在晚期试验中达到主要目标后，Zai Lab业绩大增

Reuters04-01

((自动化翻译由路透提供，请见免责声明 ))

4月1日 - ** 在美国上市的中国制药商Zai Lab Ltd 盘前股价大涨3.3%至16.55美元。

** ZLab的合作伙伴百时美施贵宝周四晚些时候表示，其药物 KRAZATI在一项针对突变非小细胞肺癌(NSCLC) 的晚期研究中达到了主要目标。

** 该药物还达到了研究的一个关键次要目标

** ZLAB预计将于今年向中国医药产品协会提交KRAZATI的新药申请，作为该适应症的二线或后线治疗药物。

** BMY将完成对现有数据的全面评估，并与卫生部门讨论评估结果

** 截至周四收盘，ZLAB 的美股累计下跌 41.4

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2424714336?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-01 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2424714336","market":"sh","top_or_hot":-1,"title":"BUZZ-肺癌药物在晚期试验中达到主要目标后，Zai Lab业绩大增","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    4月1日 - ** 在美国上市的中国制药商Zai Lab Ltd  盘前股价大涨3.3%至16.55美元。 </p><p>** ZLab的合作伙伴百时美<a href=\"https://laohu8.com/S/BMY\">施贵宝</a>  周四晚些时候表示，其药物 KRAZATI在一项针对突变非小细胞肺癌(NSCLC) 的晚期研究中达到了主要目标。</p><p>** 该药物还达到了研究的一个关键次要目标 </p><p>** ZLAB预计将于今年 向<a href=\"https://laohu8.com/S/600056\">中国医药</a>产品协会提交KRAZATI的新药申请，作为该适应症 的二线或后线治疗药物。 </p><p>     ** BMY将完成对现有数据的全面评估 ，并与卫生部门讨论评估结果</p><p>** 截至周四收盘，ZLAB 的美 股累计下跌 41.4 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-肺癌药物在晚期试验中达到主要目标后，Zai Lab业绩大增</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-肺癌药物在晚期试验中达到主要目标后，Zai Lab业绩大增\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-01 21:00 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    4月1日 - ** 在美国上市的中国制药商Zai Lab Ltd  盘前股价大涨3.3%至16.55美元。 ** ZLab的合作伙伴百时美施贵宝  周四晚些时候表示，其药物 KRAZATI在一项针对突变非小细胞肺癌(NSCLC) 的晚期研究中达到了主要目标。** 该药物还达到了研究的一个关键次要目标 ** ZLAB预计将于今年 向中国医药产品协会...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2424714336","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424714336","pubTimestamp":1711976413,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"    4月1日 - ** 在美国上市的中国制药商Zai Lab Ltd  盘前股价大涨3.3%至16.55美元。** ZLab的合作伙伴百时美施贵宝  周四晚些时候表示，其药物 KRAZATI在一项针对突变非小细胞肺癌 的晚期研究中达到了主要目标。** 该药物还达到了研究的一个关键次要目标 ** ZLAB预计将于今年 向中国医药产品协会提交KRAZATI的新药申请，作为该适应症 的二线或后线治疗药物。** BMY将完成对现有数据的全面评估 ，并与卫生部门讨论评估结果** 截至周四收盘，ZLAB 的美 股累计下跌 41.4","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4559":"巴菲特持仓","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4588":"碎股","LU1032466523.USD":"高盛全球多资产收益组合Acc","BK4526":"热门中概股","LU0882574055.USD":"富达全球健康医疗A ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","BK1161":"生物科技","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4581":"高盛持仓","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","BK4548":"巴美列捷福持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","09688":"再鼎医药","ZLAB":"再鼎医药","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BMY":"施贵宝","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","BK4532":"文艺复兴科技持仓","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","BK4531":"中概回港概念","LU0237698245.USD":"富达环球地产基金A","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK1574":"生物医药B类股","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4139":"生物科技","BK1588":"回港中概股","LU1261432733.SGD":"Fidelity World A-ACC-SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","BK4007":"制药","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC"},"translate_title":"After BUZZ-lung cancer drug achieved its main goal in late-stage trials, Zai Lab's performance increased greatly","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZLAB":0.9,"09688":0.9,"BMY":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    4月1日 - ** 在美国上市的中国制药商Zai Lab Ltd  盘前股价大涨3.3%至16.55美元。 ** ZLab的合作伙伴百时美施贵宝  周四晚些时候表示，其药物 KRAZATI在一项针对突变非小细胞肺癌(NSCLC) 的晚期研究中达到了主要目标。** 该药物还达到了研究的一个关键次要目标 ** ZLAB预计将于今年 向中国医药产品协会提交KRAZATI的新药申请，作为该适应症 的二线或后线治疗药物。      ** BMY将完成对现有数据的全面评估 ，并与卫生部门讨论评估结果** 截至周四收盘，ZLAB 的美 股累计下跌 41.4","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424714336"}